REGENXBIO Share Holder Equity 2014-2022 | RGNX
REGENXBIO share holder equity from 2014 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
REGENXBIO Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$764 |
| 2020 |
$378 |
| 2019 |
$450 |
| 2018 |
$509 |
| 2017 |
$183 |
| 2016 |
$162 |
| 2015 |
$217 |
| 2014 |
$-6 |
| 2013 |
$-2 |
REGENXBIO Quarterly Share Holder Equity
(Millions of US $) |
| 2022-03-31 |
$690 |
| 2021-12-31 |
$764 |
| 2021-09-30 |
$461 |
| 2021-06-30 |
$507 |
| 2021-03-31 |
$555 |
| 2020-12-31 |
$378 |
| 2020-09-30 |
$416 |
| 2020-06-30 |
$398 |
| 2020-03-31 |
$420 |
| 2019-12-31 |
$450 |
| 2019-09-30 |
$468 |
| 2019-06-30 |
$495 |
| 2019-03-31 |
$487 |
| 2018-12-31 |
$509 |
| 2018-09-30 |
$494 |
| 2018-06-30 |
$317 |
| 2018-03-31 |
$299 |
| 2017-12-31 |
$183 |
| 2017-09-30 |
$195 |
| 2017-06-30 |
$212 |
| 2017-03-31 |
$213 |
| 2016-12-31 |
$162 |
| 2016-09-30 |
$180 |
| 2016-06-30 |
$196 |
| 2016-03-31 |
$209 |
| 2015-12-31 |
$217 |
| 2015-09-30 |
$222 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
|
| 2014-09-30 |
$0 |
| 2013-12-31 |
$-2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.106B |
$0.470B |
|
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
|
